Phenotypic and prevalence correlation with recurrent KRAS G12C, G13D, and G22E mutations in colorectal adenocarcinoma

References

• Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. 2021 Oct;14(10):101174. doi: 10.1016/j.tranon.2021.101174
   Google Scholar
• Eldegla E, Abdel-Wahhab M, Moemen D. Association between streptococcus gallolyticus and colorectal cancer in Mansoura University hospitals. Egypt J Basic Appl Sci. 2021;8(1):397–406. doi: 10.1080/2314808X.2021.2001618
   Google Scholar
• Hong D, Fakih M, Strickler J, et al. KRAS G12C inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383(13):1207–1217. doi: 10.1056/NEJMoa1917239
   PubMed Web of Science ®Google Scholar
• Sui X, Chen Y, Liu B, et al. The relationship between KRAS gene mutation and intestinal flora in tumor tissues of colorectal cancer patients. Ann Transl Med. 2020;8(17):1085. doi: 10.21037/atm-20-5622
   PubMed Web of Science ®Google Scholar
• Ferreira A, Pereira F, Reis C, et al. Crucial role of oncogenic KRAS mutations in apoptosis and autophagy regulation: therapeutic implications. Cells. 2022;11(14):2183. doi: 10.3390/cells11142183
   PubMed Web of Science ®Google Scholar
• Vitiello P, Cardone C, Martini G. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. J Exp Clin Cancer Res. 2019;38(1):41. doi: 10.1186/s13046-019-1035-0
   PubMed Web of Science ®Google Scholar
• Korkmaz L, Coskun H, Dane F. Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish oncology group study. Surg Oncol. 2018;27(3):485–489. doi: 10.1016/j.suronc.2018.05.032
   PubMed Web of Science ®Google Scholar
• Gbolahan O, O’Neil B. Update on systemic therapy for colorectal cancer: biologics take sides. Transl Gastroenterol Hepatol. 2019;4:9. doi: 10.21037/tgh.2019.01.12
   PubMed Web of Science ®Google Scholar
• Hasbullah H, Sulong S, Che Jalil A, et al. KRAS mutational profiles among colorectal cancer patients in the east coast of Peninsular Malaysia. Diagnost (Basel). 2023;13(5):822. doi: 10.3390/diagnostics13050822
   PubMedGoogle Scholar
• Rawla P, Sunkara T, Barsouk A, et al. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019;14(2):89–103. doi: 10.5114/pg.2018.81072
   PubMed Web of Science ®Google Scholar
• Sirirat S, Paninee T, Nuntaree C, et al. Validation of a multiplex allele-specific polymerase chain reaction assay for detection of KRAS gene mutations in formalin-fixed, paraffin-embedded tissues from colorectal cancer patients. PLOS ONE. 2016;1(1):e0147672. doi: 10.1371/journal.pone.0147672
   Google Scholar
• Ana F, Vicente A, Elena A. The frequency of specific KRAS mutations, and their impact on treatment choice and survival, in patients with metastatic colorectal cancer. Oncology. 2023;28(10):e902–e909. doi: 10.1093/oncolo/oyad117
   Google Scholar
• Nikiforova M, Lynch R, Biddinger P. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–2326. doi: 10.1210/jc.2002-021907
   PubMed Web of Science ®Google Scholar
• Statistical Analysis System, User’s Guide. Statistical. Version 9.6th ed. USA Cary NC: SAS Institute Inc; 2018.
   Google Scholar
• Phipps A, Buchanan D, Makar K, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer. 2013;108(8):1757–1764. doi: 10.1038/bjc.2013.118
   PubMed Web of Science ®Google Scholar
• Judd J, Abdel Karim N, Khan H, et al. Characterization of KRAS mutation subtypes in non–small cell lung cancer. Mol Cancer Ther. 2021;20(12):2577–2584. doi: 10.1158/1535-7163.MCT-21-0201
   PubMed Web of Science ®Google Scholar
• Strickler H, Yoshino T, Stevinson K. Prevalence of KRAS G12C mutation and co-mutations and associated clinical outcomes in patients with colorectal cancer: a systematic literature review. The Oncolog. 2023;28(11):e981–e994. doi: 10.1093/oncolo/oyad138
   Google Scholar
• Yi-Jian T, Sheng H, Hung L, et al. Differences in gene mutations according to gender among patients with colorectal cancer. World J Surg Oncol. 2023;21:378. doi: 10.1186/s12957-018-1431-5
   PubMedGoogle Scholar
• Mauri G, Sartore A, Russo A, et al. Early-onset colorectal cancer in young individuals. Mol Oncol. 2019;13(2):109–131. doi: 10.1002/1878-0261.12417
   PubMed Web of Science ®Google Scholar
• Ameer A, Rana N, Haider A, et al. Investigate the role of PIK3CA gene expression in colorectal polyp development. Egypt J Basic Appl Sci. 2023;10(1):594–604. doi: 10.1080/2314808X.2023.2245992
   Google Scholar
• Choi Y, Kim N. Sex difference of colon adenoma pathway and colorectal carcinogenesis. World J Mens Health. 2024;42(2):256–282. doi: 10.5534/wjmh.230085
   PubMedGoogle Scholar
• Hayama T, Hashiguchi Y, Okamoto K. G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer. Int J Colorectal Dis. 2019;34(8):1491–1496. doi: 10.1007/s00384-019-03344-9
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Ferdous Ara J, Mili M, et al. Mutational profile of KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes in colorectal cancer patients in a tertiary care hospital, Dhaka. Adv C Biol–Metastasis. 2022;5:100054. doi: 10.1016/j.adcanc.2022.100054
   Google Scholar
• Andreyev H, Norman R, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85(5):692–696. doi: 10.1054/bjoc.2001.1964
   PubMed Web of Science ®Google Scholar
• Yu I, Paul L, Mai Y, et al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer. 2014;13(1):135. doi: 10.1186/1476-4598-13-135
   PubMedGoogle Scholar
• Qunaj L, May S, Neugut I, et al. Herzberg prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. Front Oncol. 2023;13:1252516. doi: 10.3389/fonc.2023.1252516
   PubMed Web of Science ®Google Scholar
• Carlos G, Veronica A, Ilana Z, et al. KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. BMC Gastroenterol. 2014;14(1):73. doi: 10.1186/1471-230X-14-73
   PubMedGoogle Scholar
• Soukaina B, Abdelilah L, Fatima El B, et al. Clinical significance of somatic mutations in RAS/RAF/MAPK signaling pathway in Moroccan and North African colorectal cancer patients. Asian Pac J Cancer Prev. 2022;23(11):3725–3733. doi: 10.31557/APJCP.2022.23.11.3725
   PubMedGoogle Scholar
• Kazunori T, Motohiko T, Hiroyuki S. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun. 2000;278(3):653–658. doi: 10.1006/bbrc.2000.3839
   PubMed Web of Science ®Google Scholar
• Harry H, David T, Qian S, et al. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF –wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res. 2014;20(11):3033–3043. doi: 10.1158/1078-0432.CCR-13-3140
   PubMed Web of Science ®Google Scholar
• Arrington K, Eileen H, Lee W. Prognostic and predictive roles of KRAS mutation in colorectal cancer. IJMS. 2012;13(10):12153–12168. doi: 10.3390/ijms131012153
   Google Scholar
• Mun T, Jung Y, Wan M, et al. Current advances and trends in KRAS targeted therapies for colorectal cancer. Mol Cancer Res. 2022;20(1):30–44. doi: 10.1158/1541-7786.MCR-21-0248
   PubMed Web of Science ®Google Scholar
• Shafia R, Shimon G, Michael G, et al. Therapeutic targets of KRAS in colorectal cancer. Cancers (Basel). 2021;13(24):6233. doi: 10.3390/cancers13246233
   PubMed Web of Science ®Google Scholar
• Choong E, Seung Y, Bonhan K, et al. Rapid and accurate detection of KRAS mutations in colorectal cancers using the isothermal-based optical sensor for companion diagnostics. Oncotarget. 2017;8(48):83860–83871. doi: 10.18632/oncotarget.20038
   PubMedGoogle Scholar